Zum Inhalt

HealthOSPhytotherapie & Pflanzen

Arbeitsbereiche

Nachschlagen

Phytotherapie · EMA / HMPC

Pflanzenwissen.
Mit Herkunft.

Pflanzliche Arzneidrogen, botanische Abbildungen und europäische Monographien gemeinsam recherchieren. Quellenbelegte Wirkstoffbeziehungen führen über HealthOS-IDs zu den verknüpften Begriffen.

Was dieser Bestand beschreibt

HMPC-Quellenprofile mit Originalbezeichnungen und Bearbeitungsstatus. Die lateinische Arzneidrogenbezeichnung unterscheidet beispielsweise Blätter, Wurzeln und Zubereitungen; sie wird unverändert übernommen.

Quellenprofile

1 Treffer

Seite 1 · 1 angezeigt. Namen und Zuordnungen bleiben Originalangaben des Herausgebers.

Ispaghula Seed

Plantaginis ovatae semen

Aufruf zu wissenschaftlichen Daten

Plantago ovata Forssk.

HOS-215982hmpc:plantaginis-ovatae-semen

Plantago ovata — botanische Illustration der Art

Botanische Abbildung

Plantago ovata ↗

Photo of Plantago ovata (desert plantain) on southwestern slope of Frenchman Mountain east of Las Vegas, Nevada

Artbezogene Illustration. Sie zeigt nicht automatisch die im Profil genannte Arzneidroge oder Zubereitung und dient nicht zur sicheren Bestimmung einer Giftpflanze.

Stan Shebs · CC BY-SA 3.0 · Bildquelle ↗

Bildzuordnung & Herkunft
Originalangabe im Profil
Plantago ovata Forssk.
Taxonkennung
Q311228 · Quellenrevision 2536498843
Bearbeitung
Auf maximal 1024 Pixel verkleinert, EXIF-Orientierung angewandt und als JPEG gespeichert; kein inhaltlicher Zuschnitt.
Bildquelle abgerufen
25.10.2026

Bilddatei SHA-256: 7da0a9e1f674fcc985808d39605b0eac14e4e7b5a4d14df51f673dbeeb268b74

Themengebiete laut EMA
Constipation
Ergebnis der Bewertung laut EMA
European Union herbal monograph
Kombination laut EMA
Nein
Pflanzen–Arzneimittel-Beziehungen 2 belegte Zuordnungen

Warnungen, berichtete Effekte und verneinte Studienbefunde werden getrennt ausgewiesen und mit eindeutig bezeichneten Wirkstoffen verknüpft. Jede Aussage gilt im Zubereitungs- und Anwendungskontext der Quelle. Ein klinischer Schweregrad wird daraus nicht abgeleitet.

  • carbamazepine

    Berichteter Effekt

    Etablierte Anwendung · Quellenspalte · Keine wirkstoffbezogene Einschränkung abgeleitet · Schweregrad: nicht angegeben

    Die Quelle beschreibt einen möglichen oder beobachteten Effekt; auch ein Verdachtsfall ist damit möglich. Allgemeine Warnungen und weitere Bedingungen bleiben im Originalzitat erhalten. Daraus wurde hier keine zusätzliche Einschränkung für den einzelnen Wirkstoff abgeleitet.

    HOS-215982HOS-085618RxNorm 2002

    Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products.
    Zubereitungskontext & Beleg

    Wortlaut der zugeordneten Aussage:

    Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed.
    1. Name of the medicinal product
    To be specified for the individual finished product.
    
    
    2. Qualitative and quantitative composition 1,2
    Well-established use                                            Traditional use
    
    With regard to the marketing authorisation
    application of Article 10(a) of Directive
    2001/83/EC as amended
    
    Plantago ovata Forssk. (P. ispaghula Roxb.),
    semen (ispaghula seed)
    i) Herbal substance
       Dried ripe seeds
    
    ii) Herbal preparations
        Powdered herbal substance
    
    
    
    3. Pharmaceutical form
    Well-established use                                            Traditional use
    
    Herbal substance for oral use; herbal preparation
    in solid dosage forms for oral use.
    
    The pharmaceutical form should be described by
    the European Pharmacopoeia full standard term.
    
    
    
    4. Clinical particulars
    
    4.1. Therapeutic indications
    
    Well-established use                                            Traditional use
    
    Indication 1)
    Herbal medicinal product for the treatment of
    habitual constipation.
    
    Indication 2)
    Herbal medicinal product in conditions in which
    easy defecation with soft stool is desirable, e.g. in
    cases of painful defecation after rectal or anal
    
    1
     The material complies with the Eur. Ph. monograph monograph (ref.: 01/2008:1333).
    2
      The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal
    quality guidance.
    
    
    Community herbal monograph on Plantago ovata Forssk., semen
    EMA/HMPC/304390/2012                                                                                               Page 4/10
    Well-established use                                          Traditional use
    
    surgery, anal fissures and haemorrhoids.
    
    
    4.2. Posology and method of administration
    
    Well-established use                                          Traditional use
    
    Posology
    Adolescents, adults and elderly
    
    Daily dose
    8 - 40 g herbal substance/herbal preparation in
    2 - 3 single doses
    Children from 6 to 12 years of age
    
    Daily dose
    4 - 25 g herbal substance/herbal preparation in
    2 – 3 single doses.
    
    The use in children under 6 years of age is not
    recommended (see section 4.4 ‘Special warnings
    and precautions for use’).
    
    Duration of use
    
    If the constipation does not resolve within 3 days,
    a doctor or a pharmacist should be consulted.
    
    See section 4.4 ‘Special warnings and precautions
    for use’.
    
    Method of administration
    
    A sufficient amount of liquid (water, milk, fruit
    juice or similar aqueous liquid) should always be
    taken e.g. 30 ml of water per 1 g of herbal
    substance.
    
    The medicinal product can be mixed with the
    liquids and then swallowed or taken and then
    swallowed with sufficient quantity of liquid.
    Adequate fluid intake has to be maintained.
    
    The product should be taken during the day at
    least ½ to 1 hour before or after intake of other
    medicines, not immediately prior to bed-time.
    
    The effect starts 12 - 24 hours later.
    
    Powder formulations:
    
    When preparing the product for administration, it
    is important to try to avoid inhaling any of the
    powder in order to minimise the risk of
    sensitisation to the active ingredient.
    
    
    Community herbal monograph on Plantago ovata Forssk., semen
    EMA/HMPC/304390/2012                                                            Page 5/10
    
    4.5. Interactions with other medicinal products and other forms of
    interaction
    
    Well-established use                                          Traditional use
    
    Enteral absorption of concomitantly administered
    medicines such as minerals, vitamins (B 12),
    cardiac glycosides, coumarin derivatives,
    carbamazepine and lithium may be delayed. For
    this reason the product should not be taken ½ to
    1 hour before or after intake of other medicinal
    products.
    
    Diabetic patients should take ispaghula seeds only
    under medical supervision because adjustment of
    anti-diabetic therapy may be necessary.
    
    Use of ispaghula seed concomitantly with thyroid
    hormones requires medical supervision because
    the dose of the thyroid hormones may have to be
    adjusted.
    
    
    Community herbal monograph on Plantago ovata Forssk., semen
    EMA/HMPC/304390/2012                                                            Page 7/10

    PDF SHA-256: 39a176bd67181a7662349d120e50bd9eaa879dda95a76a89f22cce24c86a4969

    Die Zuordnung verbindet dieses HMPC-Quellenprofil mit dem genannten Wirkstoff. Sie ist keine Aussage über jedes Präparat aus dieser Pflanzenart.

  • lithium

    Berichteter Effekt

    Etablierte Anwendung · Quellenspalte · Keine wirkstoffbezogene Einschränkung abgeleitet · Schweregrad: nicht angegeben

    Die Quelle beschreibt einen möglichen oder beobachteten Effekt; auch ein Verdachtsfall ist damit möglich. Allgemeine Warnungen und weitere Bedingungen bleiben im Originalzitat erhalten. Daraus wurde hier keine zusätzliche Einschränkung für den einzelnen Wirkstoff abgeleitet.

    HOS-215982HOS-085952RxNorm 6448

    Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed. For this reason the product should not be taken ½ to 1 hour before or after intake of other medicinal products.
    Zubereitungskontext & Beleg

    Wortlaut der zugeordneten Aussage:

    Enteral absorption of concomitantly administered medicines such as minerals, vitamins (B 12), cardiac glycosides, coumarin derivatives, carbamazepine and lithium may be delayed.
    1. Name of the medicinal product
    To be specified for the individual finished product.
    
    
    2. Qualitative and quantitative composition 1,2
    Well-established use                                            Traditional use
    
    With regard to the marketing authorisation
    application of Article 10(a) of Directive
    2001/83/EC as amended
    
    Plantago ovata Forssk. (P. ispaghula Roxb.),
    semen (ispaghula seed)
    i) Herbal substance
       Dried ripe seeds
    
    ii) Herbal preparations
        Powdered herbal substance
    
    
    
    3. Pharmaceutical form
    Well-established use                                            Traditional use
    
    Herbal substance for oral use; herbal preparation
    in solid dosage forms for oral use.
    
    The pharmaceutical form should be described by
    the European Pharmacopoeia full standard term.
    
    
    
    4. Clinical particulars
    
    4.1. Therapeutic indications
    
    Well-established use                                            Traditional use
    
    Indication 1)
    Herbal medicinal product for the treatment of
    habitual constipation.
    
    Indication 2)
    Herbal medicinal product in conditions in which
    easy defecation with soft stool is desirable, e.g. in
    cases of painful defecation after rectal or anal
    
    1
     The material complies with the Eur. Ph. monograph monograph (ref.: 01/2008:1333).
    2
      The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal
    quality guidance.
    
    
    Community herbal monograph on Plantago ovata Forssk., semen
    EMA/HMPC/304390/2012                                                                                               Page 4/10
    Well-established use                                          Traditional use
    
    surgery, anal fissures and haemorrhoids.
    
    
    4.2. Posology and method of administration
    
    Well-established use                                          Traditional use
    
    Posology
    Adolescents, adults and elderly
    
    Daily dose
    8 - 40 g herbal substance/herbal preparation in
    2 - 3 single doses
    Children from 6 to 12 years of age
    
    Daily dose
    4 - 25 g herbal substance/herbal preparation in
    2 – 3 single doses.
    
    The use in children under 6 years of age is not
    recommended (see section 4.4 ‘Special warnings
    and precautions for use’).
    
    Duration of use
    
    If the constipation does not resolve within 3 days,
    a doctor or a pharmacist should be consulted.
    
    See section 4.4 ‘Special warnings and precautions
    for use’.
    
    Method of administration
    
    A sufficient amount of liquid (water, milk, fruit
    juice or similar aqueous liquid) should always be
    taken e.g. 30 ml of water per 1 g of herbal
    substance.
    
    The medicinal product can be mixed with the
    liquids and then swallowed or taken and then
    swallowed with sufficient quantity of liquid.
    Adequate fluid intake has to be maintained.
    
    The product should be taken during the day at
    least ½ to 1 hour before or after intake of other
    medicines, not immediately prior to bed-time.
    
    The effect starts 12 - 24 hours later.
    
    Powder formulations:
    
    When preparing the product for administration, it
    is important to try to avoid inhaling any of the
    powder in order to minimise the risk of
    sensitisation to the active ingredient.
    
    
    Community herbal monograph on Plantago ovata Forssk., semen
    EMA/HMPC/304390/2012                                                            Page 5/10
    
    4.5. Interactions with other medicinal products and other forms of
    interaction
    
    Well-established use                                          Traditional use
    
    Enteral absorption of concomitantly administered
    medicines such as minerals, vitamins (B 12),
    cardiac glycosides, coumarin derivatives,
    carbamazepine and lithium may be delayed. For
    this reason the product should not be taken ½ to
    1 hour before or after intake of other medicinal
    products.
    
    Diabetic patients should take ispaghula seeds only
    under medical supervision because adjustment of
    anti-diabetic therapy may be necessary.
    
    Use of ispaghula seed concomitantly with thyroid
    hormones requires medical supervision because
    the dose of the thyroid hormones may have to be
    adjusted.
    
    
    Community herbal monograph on Plantago ovata Forssk., semen
    EMA/HMPC/304390/2012                                                            Page 7/10

    PDF SHA-256: 39a176bd67181a7662349d120e50bd9eaa879dda95a76a89f22cce24c86a4969

    Die Zuordnung verbindet dieses HMPC-Quellenprofil mit dem genannten Wirkstoff. Sie ist keine Aussage über jedes Präparat aus dieser Pflanzenart.

Keine oder wenige Zuordnungen bedeuten nicht, dass keine Wechselwirkungen bestehen. Nicht eindeutig zuordenbare Aussagen bleiben im Originalabschnitt nachlesbar; verneinte Befunde gelten nur für die beschriebenen Bedingungen.

Sicherheit aus der Monographie Originalabschnitte

Englische Originalabschnitte mit unveränderten Spalten für etablierte und traditionelle Anwendung. Aussagen gelten für die im Dokument genannten Zubereitungen und Anwendungsarten. Aus ihnen werden hier keine Interaktionspaare oder Schweregrade abgeleitet.

Final Community herbal monograph on Plantago ovata Forssk., semen ↗

PDF abgerufen: 27.10.2026 · 10 Seiten · automatisch ausgelesen

Zubereitungs- und Anwendungskontext · Originaltext

Originalkontext vor Abschnitt 4.3, einschließlich der Angaben zu Zubereitungen und Anwendung. Buchstaben und Nummern der Zubereitungen werden in den Sicherheitsabschnitten wieder aufgegriffen.

1. Name of the medicinal product
To be specified for the individual finished product.


2. Qualitative and quantitative composition 1,2
Well-established use                                            Traditional use

With regard to the marketing authorisation
application of Article 10(a) of Directive
2001/83/EC as amended

Plantago ovata Forssk. (P. ispaghula Roxb.),
semen (ispaghula seed)
i) Herbal substance
   Dried ripe seeds

ii) Herbal preparations
    Powdered herbal substance



3. Pharmaceutical form
Well-established use                                            Traditional use

Herbal substance for oral use; herbal preparation
in solid dosage forms for oral use.

The pharmaceutical form should be described by
the European Pharmacopoeia full standard term.



4. Clinical particulars

4.1. Therapeutic indications

Well-established use                                            Traditional use

Indication 1)
Herbal medicinal product for the treatment of
habitual constipation.

Indication 2)
Herbal medicinal product in conditions in which
easy defecation with soft stool is desirable, e.g. in
cases of painful defecation after rectal or anal

1
 The material complies with the Eur. Ph. monograph monograph (ref.: 01/2008:1333).
2
  The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal
quality guidance.


Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012                                                                                               Page 4/10
Well-established use                                          Traditional use

surgery, anal fissures and haemorrhoids.


4.2. Posology and method of administration

Well-established use                                          Traditional use

Posology
Adolescents, adults and elderly

Daily dose
8 - 40 g herbal substance/herbal preparation in
2 - 3 single doses
Children from 6 to 12 years of age

Daily dose
4 - 25 g herbal substance/herbal preparation in
2 – 3 single doses.

The use in children under 6 years of age is not
recommended (see section 4.4 ‘Special warnings
and precautions for use’).

Duration of use

If the constipation does not resolve within 3 days,
a doctor or a pharmacist should be consulted.

See section 4.4 ‘Special warnings and precautions
for use’.

Method of administration

A sufficient amount of liquid (water, milk, fruit
juice or similar aqueous liquid) should always be
taken e.g. 30 ml of water per 1 g of herbal
substance.

The medicinal product can be mixed with the
liquids and then swallowed or taken and then
swallowed with sufficient quantity of liquid.
Adequate fluid intake has to be maintained.

The product should be taken during the day at
least ½ to 1 hour before or after intake of other
medicines, not immediately prior to bed-time.

The effect starts 12 - 24 hours later.

Powder formulations:

When preparing the product for administration, it
is important to try to avoid inhaling any of the
powder in order to minimise the risk of
sensitisation to the active ingredient.


Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012                                                            Page 5/10
Kontext im Original-PDF öffnen ↗
4.3 · Gegenanzeigen

Contraindications

4.3. Contraindications

Well-established use                                          Traditional use

Hypersensitivity to the active substance (for
powder formulations add: See section 4.4 ‘Special
warnings and precautions for use’).

Patients with a sudden change in bowel habit that
persists for more than 2 weeks.

Undiagnosed rectal bleeding and failure to
defecate following the use of a laxative.

Patients suffering from abnormal constrictions in
the gastro-intestinal tract, with diseases of the
oesophagus and cardia, potential or existing
intestinal blockage (ileus), paralysis of the
intestine or megacolon.

Patients who have difficulty in swallowing or any
throat problems.
Original-PDF · Seite 5 ↗
4.4 · Warnhinweise und Vorsichtsmaßnahmen

Special warnings and precautions for use

4.4. Special warnings and precautions for use

Well-established use                                          Traditional use

The use is not recommended in children below
6 years of age due to insufficient data on efficacy.
Laxative bulk producers should be used before
using other purgatives if change of nutrition is not
successful.

A sufficient amount of liquid should always be
taken e.g. 30 ml of water per 1 g of herbal
substance.

Ispaghula seed should not be used by patients
with faecal impaction and symptoms such as
abdominal pain, nausea and vomiting unless
advised by a doctor because these symptoms can
be signs of potential or existing intestinal blockage
(ileus).

If abdominal pain occurs or in cases of any
irregularity of faeces, the use of ispaghula seed
should be discontinued and medical advice must
be sought.

When taken with inadequate fluid amounts, bulk
forming agents can cause obstruction of the
throat and oesophagus with choking and intestinal
obstruction. Symptoms can be chest pain,
vomiting, or difficulty in swallowing or breathing.


Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012                                                            Page 6/10
Well-established use                                          Traditional use

The treatment of debilitated patients and / or
elderly patients requires medical supervision.

In order to decrease the risk of gastrointestinal
obstruction (ileus) ispaghula seed should be used
together with medicinal products known to inhibit
peristaltic movement (e.g. opioids) only under
medical supervision.

Powder formulations:

Warning on hypersensitive reactions

In individuals with continued occupational contact
to powder of Plantago ovata seeds or husks (i.e.
healthcare workers, caregivers) allergic
sensitisation may occur due to inhalation, this is
more frequent in atopic individuals. This
sensitisation usually leads to hypersensitivity
reactions which could be serious (see 4.8
‘Undesirable effects’).

It is recommended to assess clinically the possible
sensitisation of individuals at risk and, if justified,
to perform specific diagnostic tests.

In case of proven sensitisation leading to
hypersensitivity reactions, exposure to the
product should be stopped immediately and
avoided in the future (see 4.3 ‘Contraindications’).
Original-PDF · Seite 5–6 ↗
4.5 · Wechselwirkungen

Interactions with other medicinal products and other forms of interaction

4.5. Interactions with other medicinal products and other forms of
interaction

Well-established use                                          Traditional use

Enteral absorption of concomitantly administered
medicines such as minerals, vitamins (B 12),
cardiac glycosides, coumarin derivatives,
carbamazepine and lithium may be delayed. For
this reason the product should not be taken ½ to
1 hour before or after intake of other medicinal
products.

Diabetic patients should take ispaghula seeds only
under medical supervision because adjustment of
anti-diabetic therapy may be necessary.

Use of ispaghula seed concomitantly with thyroid
hormones requires medical supervision because
the dose of the thyroid hormones may have to be
adjusted.


Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012                                                            Page 7/10
Original-PDF · Seite 6 ↗
4.8 · Nebenwirkungen

Undesirable effects

4.8. Undesirable effects

Well-established use                                          Traditional use

Flatulence may occur with the use of the product,
which generally disappears in the course of the
treatment. Abdominal distension and risk of
intestinal or oesophageal obstruction and faecal
impaction may occur, particularly if swallowed
with insufficient fluid. The frequency is not known.

Ispaghula contains potent allergens. The exposure
to these allergens is possible through oral
administration, contact with the skin and, in the
case of powder formulations, also by inhalation.
As a consequence to this allergic potential,
individuals exposed to the product can develop
hypersensitivity reactions such as rhinitis,
conjunctivitis, bronchospasm and in some cases,
anaphylaxis. Cutaneous symptoms such as
exanthema and/or pruritus have also been
reported. Special attention should be given to
individuals manipulating the powder formulations
routinely (see 4.4 ‘Special warnings and
precautions for use’). The frequency is not known.

If other adverse reactions not mentioned above


Community herbal monograph on Plantago ovata Forssk., semen
EMA/HMPC/304390/2012                                                            Page 8/10
Well-established use                                          Traditional use

occur, a doctor or a pharmacist should be
consulted.
Original-PDF · Seite 7–8 ↗
Dokumentfassung nachweisen

SHA-256: 39a176bd67181a7662349d120e50bd9eaa879dda95a76a89f22cce24c86a4969

Der Hash kennzeichnet die abgerufene Datei. Die Dokumentfassung und der Bearbeitungsstatus des Pflanzenprofils sind getrennte Angaben.

Importstand: 27.10.2026 · Aktuelles EMA-Quellenprofil ↗

Dokumente beim Herausgeber · 13

Originaltitel bleiben erhalten. Entwürfe, ältere Fassungen und ergänzende Berichte können nebeneinander vorliegen; der Profilstatus bestimmt nicht die Gültigkeit jedes Dokuments.

Dokumentenlinks geprüft: 27.10.2026

Quellenstand & Originalangaben
Originalstatus
C: ongoing call for scientific data
Zuletzt geändert laut EMA
15/02/2024
Erstveröffentlichung laut EMA
31/12/2009
Erfolgreicher Quellenabruf
27.10.2026
Importumfang, Dubletten & Datenherkunft

204 eindeutige Quellenprofile aus 251 Feed-Zeilen; 46 identische Dubletten zusammengefasst und 1 zusätzliche abweichende Quellenzeilen erhalten. Der Herausgeber meldet 204 Datensätze.

Die Angaben werden getrennt ausgewiesen, weil Feed-Zeilen, eindeutige Quellenprofile und die gemeldete Datensatzanzahl voneinander abweichen können.

Feed-Stand: 27.10.2026 · Erfolgreicher Abruf: 27.10.2026 · EMA-Originalfeed

SHA-256: 9e0dc2062678d51589773ddceb8f2793c7522bad5fc64f13842cf9c0582d3889